Node negative breast cancer. Beyond international consensus: A pragmatic approach;Le cancer du sein sans envahissement ganglionnaire. Au-delà des consensus internationaux: Une approche pragmatique

Bulletin du Cancer

Volumn 98, Issue 7, 2011, Pages 807-825

  Penault Llorca, Frédérique ^a   Coeffic, David ^b   Delozier, Thierry ^c   Dohollou, Nadine ^d   Freyer, Gilles ^e   Gligorov, Joseph ^f   Hardy Bessard, Anne Claire ^g   Jacot, William ^h   Misset, Jean Louis ⁱ   Nabholtz, Jean Marc ^a   Petit, Thierry ^j   Spielmann, Marc ^k   Namer, Moïse ^l  

^a CENTRE JEAN PERRIN   (France)

^b IPC   (France)

^c CENTRE FRANÇOIS BACLESSE   (France)

^d Polyclinique de Bordeaux   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f HÔPITAL TENON   (France)

^g Polyclinique Saint Brieuc   (France)

^h Centre Anticancereux   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j CENTRE PAUL STRAUSS   (France)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l Polyclinique Mougins   (France)

more..

Author keywords

Breast cancer; Chemotherapy; Elder women; HER2; Hormonotherapy; Node negative; Trastuzumab; Triple negative

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER SCREENING; HUMAN; ONCOLOGY; REVIEW;

EID: 79960499292     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1395     Document Type: Review

References (46)

1. Carlson RW, Allred DC, Anderson BO, et al. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009 ; 7 : 122-92.
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007 ; 18 : 1133-44.
3. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009 ; 20 : 1319-29.
4. Cancers du sein - recommandations pour la pratique clinique de Saint-Paul-de-Vence. Oncologie 2007 ; 9 : 593-644.
5. Cancers du sein - recommandations pour la pratique clinique de Saint-Paul-de-Vence. Oncologie 2009 ; 11 : 497-505.
6. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cmor smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 2006 ; 24 : 2113-22. (Pubitemid 46628472)
7. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997 ; 15 : 2894-904. (Pubitemid 27330017)
8. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003 ; 9 : 923-30. (Pubitemid 36323694)
9. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008 ; 26 : 5697-704.
10. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009 ; 27 : 5700-6.
11. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009 ; 27 : 5693-9.
12. Cottu PH, Rodriguez MJ, Kirova Y, et al. Treatment of infracentrimetric HER2-positive (+) invasive breast tumors. The Institut Curie experience. Cancer Res 2009 ; 69(2 suppl), abstract no 3152.
13. Joensuu H, Pylkkänen L, Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer 1999 ; 85 : 2183-9. (Pubitemid 29215557)
14. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007 ; 25 : 4952-60. (Pubitemid 350220427)
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 ; 365 : 1687-717.
16. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996 ; 14 : 2197-205. (Pubitemid 26264869)
17. Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008 ; 371 : 29-40.
18. Kiba T, Inamoto T, Nishimura T, et al. The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery. BMC Cancer 2008 ; 8 : 323.
19. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004 ; 22 : 1630-7. (Pubitemid 41079801)
20. Baak JP, van Diest PJ, Janssen EA, et al. Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Ann Oncol 2008 ; 19 : 649-54. (Pubitemid 351461033)
21. Amadori D, Nanni O, Volpi A, et al. Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis. Breast Cancer Res Treat 2008 ; 108 : 259-64. (Pubitemid 351311359)
22. Fisher B, Jeong JH, Bryant J, et al. National surgical adjuvant breast and bowel project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from national surgical adjuvant breast and bowel project randomised clinical trials. Lancet 2004 ; 364 : 858-68.
23. Fisher B, Bryant J, Dignam JJ, et al. National surgical adjuvant breast and bowel project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002 ; 20 : 4141-9. (Pubitemid 35191016)
24. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J 2008 ; 14 : 456-63.
25. Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 2009 ; 15 : 454-60.
26. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer 2008 ; 112 : 737-47.
27. Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of geriatric oncology. Lancet Oncol 2007 ; 8 : 1101-15. (Pubitemid 350182967)
28. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000 ; 5 : 224-37. (Pubitemid 30429942)
29. Lee SJ, Lindquist K, Segal MR, Covinski MR. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2009 ; 295 : 801-8. (Pubitemid 43244307)
30. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976 ; 294 : 405-10.
31. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998 ; 352 : 930-42.
32. Martin M, Villar A, Sole-Calvo A, et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 2003 ; 14 : 833-42.
33. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006 ; 24 : 5381-7. (Pubitemid 46623169)
34. Martin M, Iluch A, Segui MA, et al. Multicenter, randomized phase III study of adjuvant chemotherapy for high risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial. J Clin Oncol 2008 ; 26(15S) : 542.
35. Sparano J, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008 ; 358 : 1663-71. (Pubitemid 351549913)
36. Laporte S, Jones S, Chapelle C, Jacquin J-P, Martín M. Consistency of effect of docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: meta-analysis of 12 randomized clinical trials. Cancer Res 2009 ; 69(24 Suppl), abstract 605.
37. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 ; 353 : 1659-72. (Pubitemid 41464705)
38. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005 ; 23 : 7811-9. (Pubitemid 46657378)
39. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 ; 353 : 1673-84. (Pubitemid 41464706)
40. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim efficacy analysis. Breast Cancer Res Treat 2005 ; 94(Suppl 1), abstract ML1.
41. Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009 ; 27 : 6129-34.
42. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009 ; 27 : 5685-92.
43. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008 ; 19 : 1090-6. (Pubitemid 351796334)
44. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. Cancer Res 2009 ; 69(24 Suppl), abstract 62.
45. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 2009 ; 27 : 1177-83.
46. Jones S, Collea RP, Oratz R, et al. Cardiac safety results of a phase II trial of adjuvant docetaxel/cyclophosphamide plus trastuzumab (Her TC) in HER2+ early stage breast cancer patients. Cancer Res 2009 ; 69(24 Suppl), abstract 5082.